Jefferies Comments on Nektar Therapeutics (NKTR) After Global Healthcare Conference

Jefferies commented on Nektar Therapeutics (NASDAQ: NKTR) after CEO Howard Robin presented at the Jefferies 2012 Global Healthcare Conference.

The firm comments, "At our annual healthcare conference, NKTR CEO Howard Robin provided an update on the company's pipeline incl completion of patient enrollment for the last of the PIII KODIAC trials for naloxegol for opioid-induced constipation. Key near term catalysts include data from the KODIAC program in 4Q12/1Q13, PI data for NKTR-192 for acute pain in 2Q13, and PII data for NKTR-181 for chronic pain in mid-2013."

The firm reiterated their Buy rating and price target of $9.50.

For an analyst ratings summary and ratings history on Nektar Therapeutics click here. For more ratings news on Nektar Therapeutics click here.

Shares of Nektar Therapeutics closed at $6.70 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Nektar Therapeutics (NKTR) Tops Q2 EPS by 77c
• McGraw Hill (MH) PT Raised to $15 at UBS
• KinderCare Learning Companies (KLC) PT Lowered to $4.50 at UBS